SLC5A2 and chronic kidney disease: eGFR slope analyses from heart failure and CKD trials consistently demonstrate reduced rates of kidney function decline among people treated with SGLT-2 inhibition, including those without significant albuminuria, as demonstrated in EMPA-KIDNEY (Fig. 3) [3, 8–12].